H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $591 from $518 and keeps a Buy rating on the shares. The firm views povetacicept as “the best-in-class contender” in primary membranous nephropathy following Roche’s Phase 3 MAJESTY study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals Signals Confident Growth Beyond CF
- Vertex Pharmaceuticals price target raised to $570 from $564 at Morgan Stanley
- Vertex Pharmaceuticals price target raised to $558 from $495 at Scotiabank
- Vertex Pharmaceuticals price target lowered to $541 from $546 at RBC Capital
- Vertex Pharmaceuticals price target raised to $577 from $572 at Bernstein